Leukemia News

SALT LAKE CITY — Zanubrutinib improved outcomes compared with bendamustine/rituximab among adults with treatment-naive deletion 17p-negative chronic lymphocytic leukemia or small lymphocytic lymphoma, according to phase 3 study results.

SALT LAKE CITY — Socioeconomic disadvantage among hematopoietic stem cell transplant donors appeared associated with poorer outcomes among transplant recipients, according to study results.

SALT LAKE CITY — Early azithromycin use did not affect hematologic relapse among pediatric hematopoietic stem cell transplant recipients, according to study results.

SALT LAKE CITY — Pediatric and young adult survivors of acute leukemia who underwent allogeneic hematopoietic stem cell transplantation appeared to be at increased risk for late mortality, according to study results.

SALT LAKE CITY — Allogeneic hematopoietic stem cell transplantation appeared effective for patients with high-risk subtypes of acute lymphoblastic leukemia, according to study results.

SALT LAKE CITY — Eprenetapopt plus azacitidine maintenance therapy significantly improved outcomes for patients with TP53-mutated acute myeloid leukemia and TP53-mutated myelodysplastic syndrome, according to study results.

The FDA Oncologic Drugs Advisory Committee voted Thursday in favor of randomized data to support future approvals of phosphatidylinositol-3-kinase inhibitors, which are being developed for patients with hematologic malignancies.

BOSTON – Loriel J. Solodokin, PharmD, BCOP, discussed “a great session” on chronic myeloid leukemia presented at Hematology/Oncology Pharmacy Association Annual Meeting in a video interview with Healio.

Infection mitigation with vaccines is essential for patients with hematologic malignancies because they are at increased risk for severe infection, hospitalization and mortality if they contract COVID-19.

Acute lymphoblastic leukemia molecular subtypes and prognosis appeared associated with genetic ancestry, suggesting a possible genetic basis for racial and ethnic disparities in ALL, according to a study in JAMA Oncology.